CHICAGO – Denosumab remained well tolerated, safe, and effective for maintaining reduced bone turnover and for increasing bone mineral density after 6 years of continuous use in 2,343 postmenopausal women with increased fracture risk due to osteoporosis.
From the Annual Meeting of the American College of Rheumatology
PREVIEW